KR900009647A - 아데노신 유도체, 그들의 제법 및 사용방법 - Google Patents
아데노신 유도체, 그들의 제법 및 사용방법 Download PDFInfo
- Publication number
- KR900009647A KR900009647A KR1019890018330A KR890018330A KR900009647A KR 900009647 A KR900009647 A KR 900009647A KR 1019890018330 A KR1019890018330 A KR 1019890018330A KR 890018330 A KR890018330 A KR 890018330A KR 900009647 A KR900009647 A KR 900009647A
- Authority
- KR
- South Korea
- Prior art keywords
- methyladenosine
- cycloalkyl
- alkyl
- alkynyl
- aralkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 2
- 150000003835 adenosine derivatives Chemical class 0.000 title 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- -1 prop-2-ynyl Chemical group 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 230000024883 vasodilation Effects 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000005038 alkynylalkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical group OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- GPKUICFDWYEPTK-UHFFFAOYSA-N methoxycyclohexatriene Chemical group COC1=CC=C=C[CH]1 GPKUICFDWYEPTK-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (8)
- 하기 일반식(Ⅰ)의 6-알케닐-, 알키닐-, 시클로알킬-, 아릴- 또는 아르알킬 -2'-0- 알킬 아데노신 유도체.(상기식에서 R1은 알릴, 메트알릴, 직쇄 또는 측쇄(C3-7) 알키닐, (C3-8) 시클로알킬 또는 원자번호 9에서 35를 갖는 할로겐, (C1-4) 알킬, (C1-4) 알콕시 또는 CH|3로 서로 각각 단일 또는 이 치환된 페닐, 또는 페닐고리가 임의로 서로 각각 원자번호 9에서 35의 할로겐 (C1-4) 알킬, (C1-4) 알콕시 또는 CH3로 단일 또는 이치환된 페닐(C2-4)알킬을 의미하며, R2는 수소, (C1-4) 알킬, (C3-5) 시클로알킬 또는 원자번호 9에서 35를 갖는 할로겐이며, R3는 (C1-4) 알킬이다)
- 제1항에 있어서, 하기 일반식(Ia)의 6-알케닐-, 알키닐-, 시클로알킬-, 아릴- 또는 아르알킬 -2'-0- 알킬 아데노신 유도체.(상기식에서 R1a는 알릴, 프로프-2-이닐, 시클로 프로필, 시클로 펜틸, 시클로 헥실, 시클로 헵틸, P-메톡시 페닐, P-클로로 페닐, P-플루오로페닐, (R)-페닐-CH2-CH(CH2)-를 의미하며, R2a는 수소, 메틸, 시크리로 펜틸 또는 브롬을 의미하며, R3a 는 메틸 또는 에틸을 의미한다.)
- 제1항 또는 제2항에 있어서, 하기한 화합물 중에서 선택된 화합물, 6-시클로펜틸-2'-0-메틸아데노신, 6-P-메톡시페닐-2'-0-메틸아데노신, 6-시클로펜틸-2'-0-에틸아데노신, 2-메틸-6-시클로펜틸-2'-0-메틸아데노신, 2-브로모-6-시클로펜틸-2'-0-메틸아데노신 6-시클로프로필-2'-0-메틸아데노신, 6-시클로헥실-2'-0-메틸아데노신, 6-시클로헵틸-2'-0-메틸아데노신, 6-P-플루오로페닐-2'-0-메틸아데노신, 6-P-클로로페닐-2'-0-메틸아데노신, 6-(R)-페닐-이소프로필-2'-0-메틸아데노신, 6-알릴-2'-0-메틸 아데노신, 6-프로프-2-이닐-2'-0-메틸아데노신.
- 하기 일반식(Ⅱ)의 2'-0- 알킬 아데노신 유도체를 하기 일반식(Ⅲ)의 화합물과 반응시켜 제1항에 의한 일반식(Ⅰ)의 6-알케닐-, 알키닐-, 시클로알킬-, 아릴- 또는 아르알킬-2'-0-알킬 아데노신 유도체를 제조하는 방법.(상기식에서 R1,R2,R3는 제1항에서 정의된 의미와 같고, X는 할로겐이다).
- 제4항에 의한 제조 방법으로 제조된 6-알케닐-, 알키닐-, 시클로알킬-, 아릴- 또는 아르알킬-2'-0-알킬아데노신 유도체.
- 약학적 허용 보조제 및/또는 희석제와 함께 제1항 내지 제3항에 의한 일반식(Ⅰ)의 6-알케닐-, 알키닐-, 시클로알킬-, 아릴- 또는 아르알킬-2'-0-알킬 아데노신 유도체를 활성성분으로 함유하는 치료학적 조성물.
- 관상혈관 확장, 혈관 내피 보호, 혈액 지질 농도의 저하 및 상승된 혈압 치료를 위해 제1항 내지 제3항에 의한 일반식(Ⅰ)의 6-알케닐-, 알키닐-, 시클로알킬-, 아릴-또는 아르알킬-2'-0-알킬아데노신 유도체를 사용하는 방법.
- 관상 혈관 확장, 혈관내피보호, 혈액 지질 농도 저하 및 상승된 혈압 치료를 위한 약제의 제조를 위해 제1항 내지 제3항에 의한 일반식(Ⅰ)의 6-알케닐, 알키닐-, 시클로알킬-, 아릴- 또는 아르알킬-2'-0-알킬아데노신 유도체를 사용하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP3841881.9 | 1988-12-13 | ||
| DE3841881 | 1988-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR900009647A true KR900009647A (ko) | 1990-07-05 |
Family
ID=6369027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019890018330A KR900009647A (ko) | 1988-12-13 | 1989-12-12 | 아데노신 유도체, 그들의 제법 및 사용방법 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5534503A (ko) |
| JP (2) | JPH0725786B2 (ko) |
| KR (1) | KR900009647A (ko) |
| AT (1) | AT397964B (ko) |
| AU (1) | AU618865B2 (ko) |
| BE (1) | BE1003632A3 (ko) |
| CA (1) | CA2005110A1 (ko) |
| CH (1) | CH678327A5 (ko) |
| CS (1) | CS411191A3 (ko) |
| CY (1) | CY1829A (ko) |
| DE (1) | DE3940021C2 (ko) |
| DK (1) | DK626989A (ko) |
| ES (1) | ES2022771A6 (ko) |
| FR (1) | FR2640271B1 (ko) |
| GB (1) | GB2226027B (ko) |
| HK (1) | HK70895A (ko) |
| HU (1) | HU211248A9 (ko) |
| IE (1) | IE65506B1 (ko) |
| IL (1) | IL92634A (ko) |
| IT (1) | IT1237431B (ko) |
| LU (1) | LU87639A1 (ko) |
| MX (1) | MX9203613A (ko) |
| MY (1) | MY106333A (ko) |
| NL (1) | NL8903054A (ko) |
| NZ (1) | NZ231701A (ko) |
| PH (1) | PH27533A (ko) |
| SE (1) | SE8904186L (ko) |
| SG (1) | SG8695G (ko) |
| ZA (1) | ZA899528B (ko) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0725785B2 (ja) * | 1989-01-11 | 1995-03-22 | 日本臓器製薬株式会社 | アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物 |
| DE4037363A1 (de) * | 1990-04-09 | 1991-10-10 | Europ Lab Molekularbiolog | 2-0-alkylnukleotide sowie polymere, die solche nukleotide enthalten |
| US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| CA2092305C (en) * | 1990-09-25 | 2003-02-11 | Alfred P. Spada | Compounds having antihypertensive and anti-ischemic properties |
| HUT61567A (en) | 1990-12-07 | 1993-01-28 | Sandoz Ag | Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate |
| GB9111580D0 (en) * | 1991-05-30 | 1991-07-24 | Wellcome Found | Nucleoside derivative |
| EP0601322A3 (en) * | 1992-10-27 | 1994-10-12 | Nippon Zoki Pharmaceutical Co | Adenosine deaminase inhibitor. |
| AU2546195A (en) * | 1994-05-10 | 1995-11-29 | Novartis Ag | Adenosine derivatives |
| US6107300A (en) * | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| JP3619017B2 (ja) | 1998-06-24 | 2005-02-09 | 日本臓器製薬株式会社 | 新規アラビノシルアデニン誘導体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130136C (ko) * | 1966-10-20 | |||
| DE2628202A1 (de) * | 1976-06-23 | 1977-12-29 | Max Planck Gesellschaft | Verfahren zur herstellung von 2'-substituierten-d-ribofuranosylpurinderivaten |
| CA1239397A (en) * | 1983-08-01 | 1988-07-19 | James A. Bristol | N.sup.6-substituted adenosines |
| DE3406533A1 (de) * | 1984-02-23 | 1985-08-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten |
| AU575438B2 (en) * | 1984-10-26 | 1988-07-28 | Warner-Lambert Company | N6 - substituted deoxyribose analogues of adenosines |
| US4755594A (en) * | 1986-01-31 | 1988-07-05 | Warner-Lambert Company | N6 -substituted adenosines |
| US4780452A (en) * | 1986-09-08 | 1988-10-25 | Burroughs Wellcome Co. | F-substituted-3-β-D-ribofuranosyl-3H-imidazo[4,5-b]pyridines and pharmaceutical compositions thereof |
| AU8274187A (en) * | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Heteroaromatic derivatives of adenosine |
| JPH0723394B2 (ja) * | 1986-11-27 | 1995-03-15 | 日本臓器製薬株式会社 | 新規アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物 |
| US4962194A (en) * | 1987-04-02 | 1990-10-09 | Warner-Lambert Company | Method of preparing 51,N6-disubstituted adenosines from inosines |
| GB8729994D0 (en) * | 1987-12-23 | 1988-02-03 | Glaxo Group Ltd | Chemical compounds |
| JPH0725785B2 (ja) * | 1989-01-11 | 1995-03-22 | 日本臓器製薬株式会社 | アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物 |
-
1989
- 1989-11-10 GB GB8925439A patent/GB2226027B/en not_active Expired - Lifetime
- 1989-12-04 DE DE3940021A patent/DE3940021C2/de not_active Expired - Fee Related
- 1989-12-04 FR FR8916087A patent/FR2640271B1/fr not_active Expired - Fee Related
- 1989-12-04 BE BE8901293A patent/BE1003632A3/fr not_active IP Right Cessation
- 1989-12-08 LU LU87639A patent/LU87639A1/fr unknown
- 1989-12-11 CA CA002005110A patent/CA2005110A1/en not_active Abandoned
- 1989-12-11 NZ NZ231701A patent/NZ231701A/xx unknown
- 1989-12-11 AU AU46172/89A patent/AU618865B2/en not_active Ceased
- 1989-12-11 MY MYPI89001738A patent/MY106333A/en unknown
- 1989-12-11 IL IL9263489A patent/IL92634A/en not_active IP Right Cessation
- 1989-12-11 CH CH4442/89A patent/CH678327A5/de not_active IP Right Cessation
- 1989-12-12 AT AT0280489A patent/AT397964B/de not_active IP Right Cessation
- 1989-12-12 SE SE8904186A patent/SE8904186L/xx not_active Application Discontinuation
- 1989-12-12 JP JP1324880A patent/JPH0725786B2/ja not_active Expired - Lifetime
- 1989-12-12 IT IT04864089A patent/IT1237431B/it active IP Right Grant
- 1989-12-12 KR KR1019890018330A patent/KR900009647A/ko not_active Application Discontinuation
- 1989-12-12 PH PH39675A patent/PH27533A/en unknown
- 1989-12-12 IE IE396589A patent/IE65506B1/en not_active IP Right Cessation
- 1989-12-12 DK DK626989A patent/DK626989A/da not_active Application Discontinuation
- 1989-12-13 ES ES8904209A patent/ES2022771A6/es not_active Expired - Lifetime
- 1989-12-13 NL NL8903054A patent/NL8903054A/nl not_active Application Discontinuation
- 1989-12-13 ZA ZA899528A patent/ZA899528B/xx unknown
-
1991
- 1991-12-27 CS CS914111A patent/CS411191A3/cs unknown
-
1992
- 1992-06-26 MX MX9203613A patent/MX9203613A/es unknown
-
1994
- 1994-09-22 JP JP6227610A patent/JPH07223961A/ja active Pending
- 1994-10-27 US US08/330,043 patent/US5534503A/en not_active Expired - Fee Related
-
1995
- 1995-01-18 SG SG8695A patent/SG8695G/en unknown
- 1995-05-11 HK HK70895A patent/HK70895A/xx not_active IP Right Cessation
- 1995-06-02 HU HU95P/P00151P patent/HU211248A9/hu unknown
- 1995-12-01 CY CY182995A patent/CY1829A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU613805B2 (en) | Pyrimidinedione derivative compounds, method of producing the same and antiarrythmic agents containing the same | |
| KR900006318A (ko) | 피페리디닐 벤즈이미다졸 | |
| ES8603455A1 (es) | Un metodo para preparar derivados de piperazina | |
| FI880510A0 (fi) | Menetelmä lääkeaineena käyttökelpoisen tiatsolidinonin johdannaisen valmistamiseksi | |
| KR900009647A (ko) | 아데노신 유도체, 그들의 제법 및 사용방법 | |
| ATE26273T1 (de) | 3-indolcarboxamid-verbindungen. | |
| KR900018027A (ko) | 피페리딘 유도체, 그의 제조 방법, 및 그것을 유효성분으로 함유하는 의약용 조성물 | |
| KR890014480A (ko) | 2-피리딜아세트산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물 | |
| OA09022A (fr) | Nouveaux dérivés flavonoides pipérazyl-2 oxo-é éthylànes substitués, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. | |
| AU1083488A (en) | Use of nucleosides for the manufacture of medicament for treatment of diseases caused by retrovirus or hepatitis b virus | |
| KR860008973A (ko) | 2-피롤리돈 유도체 | |
| ATE41659T1 (de) | Benzothiazepinderivate, verfahren zur herstellung und pharmazeutische zusammensetzungen. | |
| KR890013048A (ko) | 이미다졸 유도체, 그 제법 및 그의 사용 | |
| IL88513A0 (en) | D1-5-((2-benzyl-3',4-dihydro-2h-benzopyran-6-yl)methyl)thiazolidine-2',4-dione as an anti-atherosclerosis agent | |
| KR880004810A (ko) | 소화성 궤양 치료제 | |
| KR850006429A (ko) | 새로운 시아노이미다졸 누클레오시드 유도체 및 그 제조방법 | |
| KR900004717A (ko) | 이미다졸 부정맥증 치료제 | |
| DE68922053D1 (de) | Pyridoindolderivate und Verfahren zu ihrer Herstellung. | |
| ATE18761T1 (de) | Carbamoyloxybenzhydrol-derivate, ihre herstellung und ihre pharmazeutische zusammensetzungen. | |
| GB2152508A (en) | Pyrimidine derivatives | |
| JPS51118772A (en) | Method for preparing carbostyryl derivatives | |
| NO931752D0 (no) | Oktahydronaftalenoksimderivater til inhibering av kolesterolbiosyntese, samt fremgangsmaate til fremstilling og anvendelse derav | |
| KR900701273A (ko) | 진토성 에르골린 유도체 | |
| KR920002594A (ko) | 5-이소티아졸아민 유도체 | |
| KR880001630A (ko) | 5-플루오로우라실 유도체 및 그의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |